|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
| |||||||||||||||
|
|
 |
|
|
|
|
|
|
|
|
 |
||||||
 |
 At
OneWorld Health, we have no shortage of drug leads coming to us from industry
and universities; the critical factor for moving this intellectual property
forward is the project team—the pharmaceutical scientists who diligently
work behind the scenes to bring a new drug to market. Read
more > 
 New
cure for visceral leishmaniasis: enrollment complete for final clinical
trial. As of April 9, 2004, the final patients in India
have been enrolled in the Phase III clinical trial of paromomycin to cure
visceral leishmaniasis. With final cure measured at six months after completion
of therapy, the trial will come to a close in November 2004, and the process
for regulatory approval in India will proceed into its final stage.  Donation
of University of California, Santa Barbara discovery may accelerate new
treatment for schistosomiasis. The University of California,
Santa Barbara has donated to OneWorld Health all rights to a patent that
covers the novel use of an established class of cardiovascular medicines
as a potential new treatment for schistosomiasis. Read
more > 
(links to articles are included when available)
Click here to view upcoming BBC's "Kill or Cure" schedule
|
||||||
|
|||||||
|
 |
|
|
||||
|
|
|
 |
 |
 |
|
||
 |
|
||||||
| ©2008 iOWH. All rights reserved. | Design: Formative & A Bear Knows How | |
|||||
|
|
|
|
|
|
|
|
“Kill
or Cure”: BBC to air documentary on OneWorld Health beginning May
21. Millions of television viewers worldwide will have
the opportunity in May to learn just how OneWorld Health intends to cure
deadly “kala azar” (visceral leishmaniasis) in India. This
past January, a documentary film crew followed Victoria Hale and two Indian
experts in leishmaniasis during their visit to rural Bihar, India, where
entire villages are battling this ancient and loathsome parasitic disease.
As a part of the BBC's “Kill or Cure” series on neglected
infections in the developing world, the documentary illuminates the devastating
impact this disease has on the thousands of impoverished families in rural
India, and the hope that lies in a new cure OneWorld Health is developing.
Check our website in mid-May for a listing of times the documentary will
be shown on BBC World. 
CEO
Hale speaks at Davos World Economic Forum. Victoria Hale
presented at the Davos governor's meeting for health care, at a session
entitled “The role of the private sector in international efforts
to fight AIDS, TB and malaria.” She spoke about the need for innovative
new and affordable therapies to both prevent and treat AIDS and other
neglected diseases. Speaking on the importance of unifying the global
health community, Dr. Hale stated, “SARS is an example of how quickly
and effectively humanity can be mobilized to save lives and we need the
same global commitment applied to HIV/AIDS, and developing world diseases.”
OneWorld
Health announces plan to form network of pharmaceutical scientists for
global health. On March 30, OneWorld Health announced
its intent to develop a volunteer network of pharmaceutical industry scientists
and professionals who are eager to participate in the development of medicines
for neglected diseases. The news was announced upon receipt of a grant
from the Sapling Foundation (Woodside, Calif.), which
will provide seed funding to initiate development of the community of
volunteer scientists. The concept for the volunteer scientist network
arose after the staff at OneWorld Health was contacted by hundreds of
pharmaceutical scientists globally, who offered to share their ideas,
skills, accumulated research or contacts to advance the development of
medicines for the benefit of the poorest people in the developing world.
Bridging
the Divide: OneWorld Health showcased at inaugural United Nations—UC
Berkeley conference in April. The
conference brought together scholars, practitioners, government and corporate
policy makers and leaders of non-profit organizations into a single forum
focused on the role of technology in the industrial development of the
world's emerging economies. Michael MacHarg, Associate for Development
and Partnerships, presented at the panel “Healthcare Product Development
Targeting Emerging Markets,” addressing how to define and deliver
pharmaceutical technology that is affordable, supportive of local populations
and sustainable. 
The
Lancet - Infectious Diseases, Schistosomiasis: a new target for calcium
channel blockers?, April 2004 (Vol. 4, Issue 4, p. 190):
“UCSB researchers Mark Walter and Armand Kuris have found that calcium
channel blockers (CCBs) used for treating angina and hypertension, suppress
schistosome egg production in vitro—probably, they say, by interfering
with the calcium regulation of the vitelline cells that are critical for
the formation of the schistosome eggshell.” CCBs block voltage-gated
calcium channels in a wide variety of animals and thereby inhibit the
influx of calcium from the extracellular milieu”, says Walter. “We
decided to see what effect they might have on egg production in schistosomes,
assuming that the parasites, like other multicellular organisms, possessed
externally directed calcium channels.” 
Frederick
W. Kyle, Chairman, BioRexis Pharmaceutical Corporation, is a
seasoned executive, board member, and consultant to the pharmaceutical
industry, with more than four decades of experience, including assignments
in the developing world. Mr. Kyle’s experience spans large companies,
such SmithKline Beecham Plc to small therapeutics and consulting companies,
and to the nonprofit sector with the American Red Cross’s blood
and tissue donation program in the U.S. For more than a decade he was
with SmithKline Beecham, serving in his last position as president of
the pharmaceuticals division’s worldwide commercial operations and
a member of the corporation’s board of directors. Mr. Kyle is a
trustee of Swarthmore College and the Philadelphia Orchestra. He received
his bachelor’s degree in economics from Swarthmore. 
Distinguished
Service: founding OneWorld Health staffer Tricia Taborn honored at 19th
annual James Madison Freedom of Information Awards.
The Freedom of Information Committee of the Northern California
Chapter of the Society of Professional Journalists gives formal recognition
to unsung heros protecting free speech and people's right to know. For
a decade before joining OneWorld Health, Tricia was a central figure in
helping establish the San Francisco Freedom of Information committee as
the strongest local organization and presence in the country. 
Kimberly
Barrio, Manager, Business Development,
has spent her career in international development having previously directed
a Latin-American nonprofit organization called Predevelopment (ProDesarrollo)
dedicated to consulting and training of nongovernment organizations in
strategic planning and financial management. She has held a variety of
positions in product development, project management, and consulting in
Latin America, Europe, and the US. She received an M.A. from UC Berkeley
and an MBA from Stanford University. 
Ryan
Collins, Systems Administrator, brings years of experience in
networking, workstation management and computer programming. He has worked
in collaboration with the Centers for Disease Control on the National
Environmental Public Health Tracking Network, and provided support for
the Center for Occupational and Environmental Health at the University
of California at Berkeley. He received his B.S. in information systems
management at the University of California at Santa Cruz. 
Tasleem
Kachra, Director, Infectious Disease Marketing and Logistics,
has five years of US pharmaceutical experience in marketing, project management,
and market research at Roche Pharmaceuticals. She has also worked with
various nonprofits in Kenya and Uganda serving as an internal consultant
for the Aga Khan Hospital Nairobi, where she compiled and produced the
1996 edition of the Kenyan Pharmaceutical Index, and conducted an independent
assessment of rural clinics in Masaka, Uganda. She received her MPH and
MBA from Yale University. 
Theresa
Kuo, Senior Executive Assistant, has had an extensive career
in international health, having worked with the World Health Organization
(WHO) since 1989. While at the WHO, she served with the Global Program
on AIDS (now UNAIDS) as well as the Special Program for Tropical Diseases
and Research (TDR). Prior to joining the WHO, she worked as an occupational
therapist, designing equipment for the physically handicapped. She received
her B.S in physiology from Hunter College and an M.A. in Occupational
Therapy from Columbia University. 
Augusto
Llosa, Ph.D., Technical Advisor, is an infectious disease epidemiologist,
on the ground in Bihar, India advising OneWorld Health's Phase III clinical
trial for visceral leishmaniasis. Prior to OneWorld Health, he has been
involved with studies examining Chagas disease in Honduras; the effects
of H. pylori eradication in Chiapas, Mexico; validation of a precancerous
gastric lesion scoring system on a large cohort in Linqu, China; and the
association between infection with H. pylori and subsequent development
of pancreatic cancer. He received his Masters and doctoral degrees from
Stanford University.